FDA: Eurand’s Pancreatic Enzymes Need More Work
This article was originally published in The Pink Sheet Daily
Executive Summary
Makers of porcine products are having trouble meeting new FDA guidelines, rival Altus tells “The Pink Sheet” DAILY.
You may also be interested in...
Solvay Creon May Soon Find Competitors At The Trough
Following a successful advisory committee, Solvay's Creon appears likely to become the only pancreatic enzyme product on the market with an approved NDA - at least for a little while
Solvay Creon May Soon Find Competitors At The Trough
Following a successful advisory committee, Solvay's Creon appears likely to become the only pancreatic enzyme product on the market with an approved NDA - at least for a little while
Eurand Initiates Rolling NDA For Zentase To Treat Pancreatic Insufficiency
Fewer competitors expected as FDA’s 2008 PEP guidance deadline looms; market worth $300 million to $700 million, firm tells “The Pink Sheet” DAILY.